The total return over the past 12 months is -91.48% vs. +16.94% for the S&P 500. So far it's up -87.43% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (91.48%) | N/A | N/A | N/A | N/A | N/A |
| Total Return CAGR | (91.48%) | N/A | N/A | N/A | N/A | N/A |
| Revenue CAGR | (33.89%) | (10.29%) | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Cellyan Biotechnology Co., Ltd (HKPD)
| Year | Start price | End price | HKPD Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $0.82 | $0.10 | (87.43%) | +14.51% | (101.94%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
